Literature DB >> 21679248

Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection.

Priscilla C Hsu1, Carole A Federico, Mel Krajden, Eric M Yoshida, Karen E Bremner, Frank H Anderson, Alan A Weiss, Murray D Krahn.   

Abstract

BACKGROUND AND AIM: Hepatitis C virus (HCV) infection is associated with impairment in health-related quality of life (HRQOL). The purpose of this study was to evaluate HRQOL across the HCV disease spectrum using preference-based (utility) and non-preference-based (psychometric) methods, adjusting for sociodemographic factors and co-morbidity.
METHODS: Hepatitis C virus patients (n = 751) were recruited from several tertiary care settings in Vancouver, Canada for this observational, cross-sectional cohort study. Patients completed the Health Utilities Index Mark 2/3, a self-administered time trade-off utility instrument, and the Hepatitis Quality of Life Questionnaire (SF-36 with HCV-specific items). We examined the association between HRQOL and disease stage using linear regression adjusting for age, education, marital status, income, and co-morbidities.
RESULTS: Utility scores were low across disease stage and instrument, ranging from 0.51 to 0.80. On the SF-36, the mean Physical Component Summary score ranged from 37.2 to 49.2 across disease stage, and the Mental Component Summary score ranged from 39.7 to 45.7 (United States norms = 50). In general, patients with viral clearance had the highest scores, and those with late-stage disease (cirrhosis, liver cancer) had the lowest. Multivariable linear regression showed that the effect of disease stage was modest overall. Increasing age, lower income, unattached marital status, and high comorbidity were strongly associated with impairment in HRQOL.
CONCLUSIONS: The effect of stage of disease on HRQOL is modest, although viral clearance is associated with higher HRQOL. HCV patients' HRQOL is strongly associated with concomitant illness and sociodemographic factors.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 21679248     DOI: 10.1111/j.1440-1746.2011.06813.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  27 in total

1.  Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.

Authors:  William W L Wong; Karen M Lee; Sumeet Singh; George Wells; Jordan J Feld; Murray Krahn
Journal:  CMAJ Open       Date:  2017-02-03

Review 2.  Protease inhibitors for hepatitis C: economic implications.

Authors:  Stuart J Turner; Jack Brown; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

3.  Identifying those infected with hepatitis C virus.

Authors:  Eric M Yoshida; Eberhard Renner; Philip Wong; Mel Krajden
Journal:  CMAJ       Date:  2017-06-26       Impact factor: 8.262

4.  Cost-effectiveness of screening for hepatitis C in Canada.

Authors:  William W L Wong; Hong-Anh Tu; Jordan J Feld; Tom Wong; Murray Krahn
Journal:  CMAJ       Date:  2015-01-12       Impact factor: 8.262

5.  Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument.

Authors:  Roger T Anderson; Robert W Baran; Birgitta Dietz; Eric Kallwitz; Pennifer Erickson; Dennis A Revicki
Journal:  Qual Life Res       Date:  2013-09-05       Impact factor: 4.147

6.  Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation.

Authors:  Chanh-Phong Tran; John J Kim; Jordan J Feld; William Wl Wong
Journal:  Can Liver J       Date:  2021-11-11

Review 7.  A Guide to the Economics of Hepatitis C Virus Cure in 2017.

Authors:  Benjamin P Linas; Shayla Nolen
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

8.  Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial.

Authors:  Roger T Anderson; Robert W Baran; Pennifer Erickson; Dennis A Revicki; Birgitta Dietz; Katherine Gooch
Journal:  Qual Life Res       Date:  2013-09-14       Impact factor: 4.147

9.  Comparison of direct-measured and derived short form six dimensions (SF-6D) health preference values among chronic hepatitis B patients.

Authors:  Carlos K H Wong; Elegance T P Lam; Cindy L K Lam
Journal:  Qual Life Res       Date:  2013-04-06       Impact factor: 4.147

10.  Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C.

Authors:  H Leleu; M Blachier; I Rosa
Journal:  J Viral Hepat       Date:  2014-09-15       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.